1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,030 | 2,400 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biohit Oyj: A blood test before endoscopy: a practical first step for gastric cancer prevention in Europe | 135 | GlobeNewswire (Europe) | Press release
November 10th 2026, Brussels at 9.00 a.m. EET
A blood test before endoscopy: a practical first step for gastric cancer prevention in Europe
During Gastric Cancer Awareness Month, Biohit... ► Artikel lesen | |
| 05.11. | Biohit Oyj: Blood Test Before Endoscopy Could Save €75 Million Annually | 165 | GlobeNewswire (Europe) | Biohit Oyj Press release
Helsinki, 5 November 2026 at 9.00 a.m EET
Blood Test Before Endoscopy Could Save €75 Million Annually
Biohit presents a model at the Major Social and Healthcare Seminar in which... ► Artikel lesen | |
| 03.09. | Biohit Oyj: New scientific review supports non-invasive biomarker-based triage for gastric cancer risk | 404 | GlobeNewswire (Europe) | Press release
Published on September 3, 2026 at 12:00 pm local time (EEST)New scientific review supports non-invasive biomarker-based triage for gastric cancer risk
A new scientific review published... ► Artikel lesen | |
| 05.08. | Biohit Oyj Reports Rise In H1 Bottom Line | 2 | RTTNews | ||
| 05.08. | Biohit Oyj: Biohit Group Half Year Financial Report 2026 (unaudited) | 263 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2026 (unaudited)
Biohit Oyj Half Year Financial Report 5 August 2026 at 9:30 am local time (EET)
SUMMARY
January-June 2026
Revenue EUR 7.8 million (EUR 7.4... ► Artikel lesen | |
| 03.06. | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 190 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 3, 2026 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 11.02. | Biohit Oyj: Biohit Group Financial Statement Release 2025 | 300 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025 (unaudited)
Biohit Oyj Financial Statement Release 11 February 2026 at 9:30 am local time (EET)
SUMMARY
January-December 2025
Revenue EUR 15.7 million... ► Artikel lesen | |
| 08.12.25 | Biohit Oyj: New Study Shows Normal GastroPanel Result Safely Rules Out Need for Gastroscopy | 265 | GlobeNewswire (Europe) | Biohit Oyj Press Release8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MBX BIOSCIENCES | 55,94 | 0,00 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| ERASCA | 15,655 | -0,03 % | Erasca GAAP EPS of -$0.15 misses by $0.01 | ||
| TANGO THERAPEUTICS | 25,500 | 0,00 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| VIR BIOTECHNOLOGY | 9,970 | +0,10 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| CG ONCOLOGY | 74,36 | -0,05 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,140 | -0,07 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,68 | -0,14 % | Praxis Precision Medicines stellt Markteinführungspläne für zwei Medikamentenkandidaten vor | ||
| RELAY THERAPEUTICS | 18,090 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,810 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,690 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ABSCI | 8,440 | -0,12 % | Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start | ||
| PRIME MEDICINE | 4,270 | 0,00 % | Prime Medicine closes $143.7M public offering at $3.50/share | ||
| AMYLYX PHARMACEUTICALS | 30,300 | +0,03 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| PARABILIS MEDICINES | 28,430 | 0,00 % | Liberty Defense zahlt Darlehen über 2,45 Millionen US-Dollar an Parabilis vollständig zurück |
BIOHIT OYJ gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,215 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.